Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds

doi:10.3389/fimmu.2017.00038

KMS > 免疫化学研究所 > 特聘教授组 > Sachdev S.Sidhu组

	Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds
	Liu, Hongyan1 ; Saxena, Abhishek1 ; Sidhu, Sachdev S.1,2,3 ; Wu, Donghui1
	2017-01-26
发表期刊	FRONTIERS IN IMMUNOLOGY (IF:5.7[JCR-2023],6.8[5-Year])
ISSN	1664-3224
卷号	8
发表状态	已发表
DOI	10.3389/fimmu.2017.00038
摘要	Therapeutic monoclonal antibodies have become molecules of choice to treat autoimmune disorders, inflammatory diseases, and cancer. Moreover, bispecific/multispecific antibodies that target more than one antigen or epitope on a target cell or recruit effector cells (T cell, natural killer cell, or macrophage cell) toward target cells have shown great potential to maximize the benefits of antibody therapy. In the past decade, many novel concepts to generate bispecific and multispecific antibodies have evolved successfully into a range of formats from full bispecific immunoglobulin gammas to antibody fragments. Impressively, antibody fragments such as bispecific T-cell engager, bispecific killer cell engager, trispecific killer cell engager, tandem diabody, and dual-affinity-retargeting are showing exciting results in terms of recruiting and activating self-immune effector cells to target and lyse tumor cells. Promisingly, crystallizable fragment (Fc) antigen-binding fragment and monomeric antibody or half antibody may be particularly advantageous to target solid tumors owing to their small size and thus good tissue penetration potential while, on the other hand, keeping Fc-related effector functions such as antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cell-mediated phagocytosis, and extended serum half-life via interaction with neonatal Fc receptor. This review, therefore, focuses on the progress of Fc engineering in generating bispecific molecules and on the use of small antibody fragment as scaffolds for therapeutic development.
关键词	mAbs Fc region FcRn bispecific monovalent heterodimer monomeric Fc Fc antigen-binding
收录类别	SCI
语种	英语
资助项目	National Natural Science Foundation of China[81572698]
WOS研究方向	Immunology
WOS类目	Immunology
WOS记录号	WOS:000392744600001
出版者	FRONTIERS MEDIA SA
WOS关键词	NATURAL-KILLER-CELLS ; MONOMERIC IGG1 FC ; SINGLE HUMAN CD4 ; ANTIGEN-BINDING ; IN-VIVO ; HIV-1 INHIBITORS ; FRAGMENT FCAB ; LIGHT-CHAIN ; GAMMA-RI ; ANTI-CD30/CD16A ANTIBODY
原始文献类型	Review
引用统计	正在获取...
文献类型	期刊论文
条目标识符	https://kms.shanghaitech.edu.cn/handle/2MSLDSTB/1529
专题	免疫化学研究所_特聘教授组_抗体工程学实验室免疫化学研究所_特聘教授组_功能筛选实验室
通讯作者	Sidhu, Sachdev S.; Wu, Donghui
作者单位	1.ShanghaiTech Univ, Shanghai Inst Adv Immunochem Studies, Lab Antibody Engn, Shanghai, Peoples R China 2.Univ Toronto, Terrence Donnelly Ctr Cellular & Biomol Res, Banting & Best Dept Med Res, Toronto, ON, Canada 3.Univ Toronto, Terrence Donnelly Ctr Cellular & Biomol Res, Dept Mol Genet, Toronto, ON, Canada
第一作者单位	免疫化学研究所
通讯作者单位	免疫化学研究所
第一作者的第一单位	免疫化学研究所
推荐引用方式 GB/T 7714	Liu, Hongyan,Saxena, Abhishek,Sidhu, Sachdev S.,et al. Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds[J]. FRONTIERS IN IMMUNOLOGY,2017,8.
APA	Liu, Hongyan,Saxena, Abhishek,Sidhu, Sachdev S.,&Wu, Donghui.(2017).Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds.FRONTIERS IN IMMUNOLOGY,8.
MLA	Liu, Hongyan,et al."Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds".FRONTIERS IN IMMUNOLOGY 8(2017).